Drug intelligence / Profile preview

DWC20163

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules

Overview

DWC20163 is an investigational small molecule drug developed by Daewoong Pharmaceutical. It has been studied in a Phase 1 clinical trial to assess drug-drug interactions with other investigational agents (DWC20155 and DWC20156) in healthy volunteers. The specific mechanism of action, therapeutic area, and target indications for DWC20163 have not been publicly disclosed as of June 2025. Its development status is currently pending, with no reported approvals or advanced clinical phases beyond early-stage safety and pharmacokinetic studies[1][2][3].

Beyond the preview

Go deeper on DWC20163.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC20163.

Explore the full profile